Search Within

Center for Pancreatic Cancer Research

Formats
  1. Journal Article (5064)
  2. Meeting Abstract (2483)
  3. Book Section (225)
  4. Review (221)
  5. Editorial (135)
  6. Conference Paper (75)
  7. Correspondence (48)
  8. Research Letter (43)
  9. Miscellaneous (41)
  10. Guidelines (38)
  11. Book Whole (20)
Groups
  1. Department of Medicine (3946)
  2. Solid Tumor Oncology Division (3243)
  3. Surgery (3170)
  4. GSK Faculty (2916)
  5. Epidemiology and Biostatistics (2527)
  6. Gastrointestinal Oncology Service (2298)

More Groups

People
  1. Mithat Gonen (1036)
  2. William Jarnagin (913)
  3. Eileen O'Reilly (795)
  4. Michael D'Angelica (789)
  5. T Peter Kingham (622)
  6. David Kelsen (538)

More People

Years
  1. 2025 (294)
  2. 2024 (497)
  3. 2023 (523)
  4. 2022 (602)
  5. 2021 (555)
  6. 2020 (562)

More Years

Publications
  1. Journal of Clinical Oncology (927)
  2. Annals of Surgical Oncology (397)
  3. Cancer Research (226)
  4. International Journal of Radiation Oncology, Biology, Physics (219)
  5. Laboratory Investigation (209)
  6. Modern Pathology (191)

More Publications

Publishers
  1. American Society of Clinical Oncology (1003)
  2. Springer (842)
  3. Elsevier Inc. (757)
  4. Nature Publishing Group (633)
  5. American Association for Cancer Research (551)
  6. Elsevier Science, Inc. (510)

More Publishers

Results (8393)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacogenomic blood-based assay to predict chemotherapy response and survival in pancreatic cancer
    Meeting Abstract

    Yu, K. H.; McCarthy, B.; Isacoff, W. H.; Cooper, B.; Bartlett, A.; Park, J.; Purcell, F.; McCarthy, D.; O'Reilly, E. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
    Meeting Abstract

    Reni, M.; Kindler, H. L.; Hammel, P.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns
    Meeting Abstract

    Sahai, V.; Tabernero, J.; Van Cutsem, E.; Reni, M.; Tempero, M. A.; O'Reilly, E. M.; Berlin, J.; Riess, H.; Goldstein, D.; Li, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC)
    Meeting Abstract

    Oh, D. Y.; Ajani, J. A.; Bang, Y. J.; Chung, H. C.; Lacy, J.; Lee, J.; Macarulla, T.; Manji, G. A.; O'Reilly, E. M.; Allen, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK)
    Meeting Abstract

    Momtaz, P.; O'Connor, C. A.; Chou, J. F.; Capanu, M.; Yu, K. H.; Varghese, A. M.; Park, W.; Zervoudakis, A.; Li, J.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients
    Meeting Abstract

    O'Reilly, E. M.; Surinach, A.; Dillon, A.; Cockrum, P.; Yu, K. H.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Real-world patterns of care among patients with metastatic pancreatic cancer (mPC)
    Meeting Abstract

    O'Reilly, E. M.; Surinach, A.; Wu, Z.; Cockrum, P.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) plus /- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation
    Meeting Abstract

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P)
    Meeting Abstract

    Macarulla, T.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
    Meeting Abstract

    Hall, M. J.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save